Immunogenicity Assessment on Clinical Trials of SARS-CoV-2 Vaccines
DOI:
https://doi.org/10.24293/ijcpml.v28i2.1975Keywords:
COVID-19, vaccine, immunogenicityAbstract
Various strategies for dealing with COVID-19 have been carried out since the WHO declared COVID-19 as an international health emergency. One of the preventive strategies is the development of vaccines. Various vaccines have been developed worldwide. As of April 13, 2021, there were 184 vaccine candidates in the pre-clinical phase and 16 vaccine candidates currently in phase III clinical trials using several platforms, such as inactivated viruses, vector viruses, and protein subunits, and mRNA. Clinical trials of the SARS-CoV-2 vaccine include a screening test consisting of thorough physical examination and laboratory tests. The safety of clinical trials is evaluated based on laboratory test results referring to the standard toxicity grading scale. Immunogenicity assessment at the stage of clinical trials of vaccines includes assessment of humoral and cellular immunogenicity. The humoral immunogenicity test measures the ability of antibodies to neutralize the virus with the live virus neutralization test, Pseudo Virus Neutralization Test (pVNT), and Surrogate Virus Neutralization Test (sVNT) method. The cellular immunogenicity response aims to assess the immune response that leads to the Th1-cell phenotype. The COVID-19 vaccine under development is expected to trigger a helper 1 (Th1) cell response. Th1-producing Interferon-g (IFNg) is formed during acute viral infection, and Th1-type immune response correlates with milder disease. This is one of the considerations in vaccination. Th1-cell phenotype as part of cellular immunogenicity can be evaluated with ELISPOT, interferon-gamma release assay, and flow cytometry using blood samples that have been cultured with the administration of specific SARS-CoV-2 peptides. This literature review aims to study various immunogenicity assessments in the laboratory for clinical trials of COVID-19 vaccines.
Downloads
References
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of Coronavirus Disease (COVID-19) outbreak. J Autoimmun, 2020; (PG-102433): 102433.
Iqbal Yatoo M, Hamid Z, Rather I, Nazir QUA, Bhat RA, et al. Immunotherapies and immunomodulatory approaches in clinical trials-a mini-review. Hum Vaccin Immunother, 2021; 17(7): 1897-1909.
Jeyanathan M, Afkhami S, Small F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol, 2020; 20(10): 615-632.
Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing-An overview. Vaccine, 2017; 35(33): 4064-4071.
Krammer F. SARS-CoV-2 vaccines in development. Nature, 2020; 586: 516-527.
The path Malaria Vaccine Initiative (VMI). Clinical trials steps in malaria vaccine development. Available from: https://vaccine-safety-training.org/tl_files/vs/pdf/MVI.pdf. (accessed March 12, 2022).
IFPMA. The complex journey of a vaccine. International Federation of Pharmaceutical Manufacturers & Association. Available from:
https://www.ifpma.org/wp-content/uploads/2019/07/IFPMA-ComplexJourney-2019_FINAL.pdf(accessed October 23, 2021).
WHO. Guidelines on clinical evaluation of vaccines: Regulatory expectations. WHO, 2016; 1-92.
Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R. An mRNA vaccine against SARS-CoV-2-preliminary report supplementary
protocol). The New England Journal of Medicine 2020;
: 1920-1931. Available from: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/
nejmoa2022483_protocol.pdf (accessed October 23, 2021).
European medicines agency. Guideline on clinical
evaluation of vaccines. 2018. Available from: https://www.ema.europa.eu/en/documents/scientific -guideline/draft-guideline-clinical-evaluation -vaccines-revision-1_en.pdf (accessed October 16, 2021).
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 2020; 586: 589-593. Av a i l able from: https ://doi .org/10.1038/s41586-020-2639-4 (accessed November 18, 2021).
Lu Y, Wang J, Li Q, Hu H, Lu J, Chen Z. Advances in neutralization assays for sARS-CoV-2. Scand J Immunol, 2021; 94: e13088.
Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization, and pseudotyped
virus neutralization assays. Nat Protoc, 2021; 16: 3114-3140.
Morales-Núñez JJ, Muñoz-Valle JF, Torres-Hernández PC, Hernández-Bello J. Overview of neutralizing antibodies and their potential in COVID-19. Vaccines, 2021; 9(12): 1376.
Tan CW, Chia WN, Qin X, Liu P, Chen MIC, Tiu C et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol, 2020; 38:
-1078.
Goyal K, Goel H, Baranwal P, Tewary A, Dixit A, et al. Immunological mechanisms of vaccine-induced protection against SARS-CoV-2 in Humans. Immuno, 2021; 1(4): 442-456.
Manish Sadarangani, Arnaud Marchant, R. Kollmann. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.
Immunology, 2021; 21: 475-484.
Katie JE, Jordan RB, Sandra BR, Hannah ST. Cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021; 27: 270-278.
Martínez-Gallo M, Esperalba-Esquerra J, Pujol-Borrell R, Sanda V. T-cell responses as a correlate of COVID-19 vaccination. A pilot study in health care workers. MedRxiv, 2021. Available from: https://www.
medr x i v .org/ cont ent/10 .1 1 01/2 02 1 .0 3.31 . 21254472v2.full-text (accessed November 18, 2021).
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
